Document Detail

Clinical Pearls for Initiating and Utilizing Liraglutide in Patients With Type 2 Diabetes.
MedLine Citation:
PMID:  23204146     Owner:  NLM     Status:  Publisher    
This review presents clinical pearls for initiating liraglutide (Victoza®, Novo Nordisk Inc) therapy for the management of type 2 diabetes and selecting patients who will benefit from liraglutide therapy. Liraglutide, a once-daily glucagon-like peptide 1 receptor agonist, is Food and Drug Administration approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Liraglutide is effective for reducing hemoglobin A(1c) levels by 0.8% to 1.5% in patients with type 2 diabetes as monotherapy or in combination with other diabetic medications (such as metformin, sulfonylureas, rosiglitazone, or basal insulin) when compared with placebo and these other diabetic medications, including exenatide. Overweight or obese patients with type 2 diabetes or those with insulin resistance are good candidates for liraglutide therapy because liraglutide use is associated with weight loss (about 2%-4% of initial body weight) and improved β-cell function. The incidence of hypoglycemia with liraglutide is low; therefore, liraglutide would be a safe therapy choice for patients at risk or with a history of symptomatic or severe hypoglycemia. Nausea seems to be the most problematic adverse effect associated with liraglutide therapy, but it is usually transient and is minimized with dose titration.
Benjamin Gross
Related Documents :
25098406 - Addressing the needs of latinos with type 2 diabetes through online patient education.
24034516 - What are the preferred strategies for control of glycaemic variability in patients with...
23586406 - The roadmap to close the gap for vision-diabetes-related eye care in the indigenous aus...
23590576 - Association between seizures and diabetes mellitus: a comprehensive review of literature.
3886476 - Plasma levels of glucose, alanine, lactate, and beta-hydroxybutyrate in the unfed spiny...
14610526 - Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disea...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-2
Journal Detail:
Title:  Journal of pharmacy practice     Volume:  -     ISSN:  1531-1937     ISO Abbreviation:  J Pharm Pract     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8900945     Medline TA:  J Pharm Pract     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Associate Professor, Lipscomb University College of Pharmacy and Health Sciences.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacist-Developed Sedation Protocol and Impact on Ventilator Days.
Next Document:  The Frequency of Adjusted Renal Dosing of Tenofovir DF and Its Effects on Patient Outcomes.